Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thrombosis prophylaxis and coagulation activation during neoadjuvant treatment in pancreatic cancer
2024-512475-12-01Phase 4Authorised
- Sponsor
- University of Helsinki
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tinzaparin and enoxaparin in pancreatic cancer (PC), venous thromboembolism (VTE) and arterial thrombosis (2 arms), sponsored by University of Helsinki. Planned start Nov 2024; status: authorised.
02
Drugs
tinzaparinenoxaparin
03
Conditions
pancreatic cancer (PC)venous thromboembolism (VTE)arterial thrombosis
Beyond the preview
Go deeper on 2024-512475-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512475-12-01.